Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Endocrine 1

Conditions

Melanoma 137Carcinoma, Non-Small-Cell Lung 38Carcinoma, Renal Cell 33Neoplasm Metastasis 32Prostatic Neoplasms 22Brain Neoplasms 21Lung Neoplasms 20Pancreatic Neoplasms 19Uveal Melanoma 17Neoplasms 17Carcinoma, Hepatocellular 13Breast Neoplasms 13Sarcoma 12Skin Neoplasms 10Kidney Neoplasms 10Urinary Bladder Neoplasms 9Squamous Cell Carcinoma of Head and Neck 9Glioblastoma 9Triple Negative Breast Neoplasms 8Ovarian Neoplasms 8Colorectal Neoplasms 8Carcinoma, Transitional Cell 8Small Cell Lung Carcinoma 7Multiple Myeloma 7Colonic Neoplasms 7Clear-cell metastatic renal cell carcinoma 7Recurrence 6Myelodysplastic Syndromes 6Diabetes Mellitus, Insulin-Dependent, 12 6Uterine Cervical Neoplasms 5

Interventions

Topotecan 3pembrolizumab 2Gemcitabine 2vinflunine 1bemiparin 1belotecan 1apalutamide 1Temozolomide 1Taxes 1Sorafenib 1Penfluridol 1Pemetrexed 1Paclitaxel 1Nortriptyline 1Nivolumab 1Ipilimumab 1Etoposide 1Docetaxel 1Cisplatin 1Carboplatin 1Arsenic Trioxide 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Small Cell × Ipilimumab × Clear all
NCT03333616 2026-01-21

Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
100 enrolled
EndocrineGenitourinary

Penile Neoplasms, Urogenital Neoplasms, Adrenocortical Carcinoma, Carcinoma, Small Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡